Skip to content
  • HOME
  • CONFERENCE INFORMATION
    • Welcome Letter
    • Conference Chair
    • General Information
    • Conference Format
    • Target Audience
  • Program
    • Conference Program
    • Speakers
  • ABSTRACTS
    • Call for Abstracts
    • Abstract Topics
    • Instructions for E-Poster Presentations
  • Registration
    • Registration
  • Sponsorship Opportunities
    • Sponsorship Opportunities
    • Sponsors & Exhibitors
  • CONTACT US

Miami Debates in Hematologic Malignancies

Virtual Conference

27 January 2022
Register
Program
  • HOME
  • CONFERENCE INFORMATION
    • Welcome Letter
    • Conference Chair
    • General Information
    • Conference Format
    • Target Audience
  • Program
    • Conference Program
    • Speakers
  • ABSTRACTS
    • Call for Abstracts
    • Abstract Topics
    • Instructions for E-Poster Presentations
  • Registration
    • Registration
  • Sponsorship Opportunities
    • Sponsorship Opportunities
    • Sponsors & Exhibitors
  • CONTACT US
Register
Program

GOLD SPONSOR

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive’s goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary .

Miami Debates in Hematologic Malignancies

is organized by Bioevents Ltd.

#MDHM2022

Join our online community:
Contact Us

 

US:       +1-857-400-0035
UK:      +44-203-051-4032
Email:  info@bioevents-congress.com

Copyright © 2015 BioEvents.net. All Rights Reserved
Terms Of Use
Privacy Policy
Powered By Form Wizard
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT